- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00177047
Autologous Transplant for Multiple Myeloma
Autologous Transplantation for Multiple Myeloma
Study Overview
Status
Conditions
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Locations
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55455
- Masonic Cancer Center, University of Minnesota
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Patients meeting the Durie and Salmon criteria for initial diagnosis of multiple myeloma, requiring therapy and meeting one of the following:
- After initial therapy in either first complete or partial remission or no objective response
- After achieving initial response and later disease progression, patient will be eligible after subsequent therapy upon achievement of either complete or partial response
- Is not eligible or has refused any protocols of higher priority
- 18 - 75 years of age
Adequate organ function defined as:
- Hematologic: hemoglobin ≥ 8 gm/dl (untransfused), white blood cells (WBC) ≥ 3000/μl, absolute neutrophil count (ANC) ≥ 1500/μl, platelets ≥ 100,000/μl (untransfused)
- Cardiac: no active ischemia, left ventricular ejection fraction > 45% by MUGA scan
- Hepatic: bilirubin < 2.0 mg/dl, ALT < 3x the upper limit of normal
- Pulmonary: FEV1-Forced Expiratory Volume in One Second AND Forced vital capacity (FVC) >50% predicted and Carbon Monoxide Diffusing Capacity (DLCO) (corrected) > 50% predicted
- Performance status: Karnofsky performance of > 80%.
- Free of active uncontrolled infection at the time of study entry.
- At time of study enrollment > 4 weeks from prior myelosuppressive chemotherapy; and > 6 weeks from prior nitrosoureas.
- Patients must exercise informed voluntary consent and sign a consent form approved by the University of Minnesota IRB: Human Subjects Committee.
Exclusion Criteria:
- Patients will be ineligible if they have advanced myeloma refractory and unresponsive to salvage chemotherapy regimens.
- Female patients who are pregnant (positive b-HCG) or breastfeeding will be excluded from study entry. In addition fertile men or women unwilling to use contraceptive techniques during and for 12 months following treatment, particularly after thalidomide will also be excluded from study entry.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Chemotherapy and Transplant Treatment
Patients receiving peripheral blood stem cell mobilization, chemotherapy (cyclophosphamide + Mesna, growth factor (Granulocyte-colony stimulating factor) and autologous Peripheral Blood Stem Cell transplant with high dose melphalan (200 mg/m^2).
Post-transplant maintenance therapy is then prescribed if appropriate.
|
As part of the stem cell transplant process, patients receive high doses of chemotherapy and/or radiation to treat their underlying disease, such as cancer.
As one of its effects, this treatment also kills the healthy stem cells that are already in the marrow.
The transplant provides new stem cells for the patient from a healthy donor; that replace the bone marrow and allow the blood counts to recover.
Other Names:
Cyclophosphamide: 4mg/m^2 + Mesna.
Mesna is used to reduce the undesired side effects of certain chemotherapy drugs.
Other Names:
Administered intravenously 200 mg/m^2
Other Names:
Administered intravenously 10 ug/kg/day pretransplant then 5 ug/kg/day post-transplant.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants Achieving a Complete Response
Time Frame: 100 Days post transplant
|
Myeloma Response Definitions - Using International Uniform Response Criteria: Stringent Complete Response (sCR)requires, plus CR:
Complete Response (CR):
|
100 Days post transplant
|
Number of Participants Achieving a Complete Response
Time Frame: 6 months post transplant
|
Myeloma Response Definitions - Using International Uniform Response Criteria: Stringent Complete Response (sCR)requires, plus CR:
Complete Response (CR):
|
6 months post transplant
|
Number of Participants Achieving a Complete Response
Time Frame: 12 months post transplant
|
Myeloma Response Definitions - Using International Uniform Response Criteria: Stringent Complete Response (sCR)requires, plus CR:
Complete Response (CR):
|
12 months post transplant
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Patients With Extended Disease-free Survival
Time Frame: 36 Months
|
Extended disease free survival will be defined as percentage of patients surviving more than 36 months without relapse or disease progression.
|
36 Months
|
Number of Participants With Overall Survival
Time Frame: 1 year
|
The percentage of people in a study or treatment group who are alive for a certain period of time after they were diagnosed with or treated for a disease, such as cancer.
Also called survival rate.
|
1 year
|
Number of Participants With Overall Survival
Time Frame: 2 years
|
The percentage of people in a study or treatment group who are alive for a certain period of time after they were diagnosed with or treated for a disease, such as cancer.
Also called survival rate.
|
2 years
|
Number of Participants With Overall Survival
Time Frame: 3 years
|
The percentage of people in a study or treatment group who are alive for a certain period of time after they were diagnosed with or treated for a disease, such as cancer.
Also called survival rate.
|
3 years
|
Count of Participants Experiencing Transplant Related Mortality
Time Frame: 1 year
|
In the field of transplantation, toxicity is high and all deaths without previous relapse or progression are usually considered as related to transplantation.
|
1 year
|
Number of Participants Experiencing Incidence of Relapse
Time Frame: 1 year
|
The return of disease after its apparent recovery/cessation.
|
1 year
|
Number of Participants With Disease Progression
Time Frame: 1 year
|
Myeloma Response Definitions - Using International Uniform Response Criteria: Progressive Disease (PD) For patients not in CR or sCR, progressive disease requires one or more of the following:
|
1 year
|
Time to Progression
Time Frame: 1 year
|
Mean number of days among patients progressing
|
1 year
|
Time to Relapse
Time Frame: 1 year
|
Mean number of days among patients relapsing
|
1 year
|
Number of Participants With Absolute Neutrophil Recovery
Time Frame: Day 42
|
Hematologic recovery is defined by absolute neutrophil count (ANC) >2500/μl and platelets > 100,000/μl
|
Day 42
|
Time to Attainment of CR
Time Frame: 12 months post transplant
|
Mean (STD) among patients achieving complete remission (CR) Myeloma Response Definitions - Using International Uniform Response Criteria: Complete Response (CR):
|
12 months post transplant
|
Time to Attainment of CR+PR
Time Frame: 12 months post transplant
|
Mean (STD) among patients achieving complete remission (CR) and partial remission (PR) Myeloma Response Definitions - Using International Uniform Response Criteria: Complete Response (CR):
Partial Response (PR):
|
12 months post transplant
|
Duration of Maintenance Treatment
Time Frame: During study
|
During study
|
|
Dropout Rate From Maintenance Therapy
Time Frame: Post transplant phase
|
Post transplant phase
|
|
Number of Participants With Toxicities
Time Frame: By first 100 days
|
Occurrence of toxicities by first 100 days of transplant
|
By first 100 days
|
Number of Participants With Infections
Time Frame: By first 100 days
|
Occurrence of infections in the patients by the first 100 days of transplant
|
By first 100 days
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Immunoproliferative Disorders
- Hematologic Diseases
- Hemorrhagic Disorders
- Hemostatic Disorders
- Paraproteinemias
- Blood Protein Disorders
- Multiple Myeloma
- Neoplasms, Plasma Cell
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antirheumatic Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Myeloablative Agonists
- Adjuvants, Immunologic
- Cyclophosphamide
- Lenograstim
- Melphalan
Other Study ID Numbers
- 2004LS001
- MT2003-13 (Other Identifier: Blood and Marrow Transplantation Program)
- 0312M54569 (Other Identifier: IRB, University of Minnesota)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Myeloma
-
Lawson Health Research InstituteThe Ottawa Hospital; Hamilton Health Sciences Corporation; Dalhousie University; Niagara Health SystemActive, not recruitingMultiple Myeloma in Relapse | Multiple Myeloma With Failed Remission | Multiple Myeloma Stage I | Multiple Myeloma Progression | Multiple Myeloma Stage II | Multiple Myeloma Stage IIICanada
-
National Cancer Institute (NCI)Active, not recruitingSmoldering Multiple Myeloma | Refractory Multiple Myeloma | DS Stage I Multiple Myeloma | DS Stage II Multiple Myeloma | DS Stage III Multiple MyelomaUnited States
-
Fred Hutchinson Cancer Research Center/University...National Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)TerminatedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
Mayo ClinicCompletedMultiple Myeloma | Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
National Cancer Institute (NCI)TerminatedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
National Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
City of Hope Medical CenterCompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
University of WashingtonNational Cancer Institute (NCI)TerminatedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
Clinical Trials on Stem Cell Transplant
-
Azienda Ospedaliera San Giovanni BattistaCompleted
-
Ann & Robert H Lurie Children's Hospital of ChicagoWithdrawn
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Terminated
-
University of UtahTerminatedHigh Risk Hematologic MalignanciesUnited States
-
St. Jude Children's Research HospitalCompletedAnemia, Aplastic | Diamond-Blackfan Anemia | Amegakaryocytic Thrombocytopenia | Kostmann SyndromeUnited States
-
Royal Marsden NHS Foundation TrustCompleted
-
Center for International Blood and Marrow Transplant...National Cancer Institute (NCI); National Institutes of Health (NIH); National...RecruitingMyelofibrosisUnited States
-
Royal Marsden NHS Foundation TrustCompleted
-
University of Colorado, DenverCompletedHyperglycemia | Hypoglycemia | Stem Cell Transplant ComplicationsUnited States
-
National Cancer Institute (NCI)TerminatedAcute Lymphoblastic Leukemia | Acute Myelogenous Leukemia | Chronic Myelogenous Leukemia | Non-Hodgkins Lymphoma | Hodgkins LymphomaUnited States